Characteristics of patients with B-CLL patients and CER production in rituximab-treated B-CLL cells
Patient . | Age, y . | Lymphocytosis, mm3 . | Duration from diagnosis, y . | Previous therapy . | CER accumulation, % . |
|---|---|---|---|---|---|
| 1 | 80 | 38 600 | 0 | No | +41 |
| 2 | 58 | 32 600 | 0.3 | No | +75 |
| 3 | 60 | 82 000 | 0 | No | +23 |
| 4 | 74 | 59 800 | 0 | No | +36 |
| 5 | 66 | 30 600 | 4 | CBL, CVP | NS |
| 6 | 66 | 70 100 | 11 | CBL, CVP | +80 |
| 7 | 75 | 19 100 | 11 | CBL | +13 |
| 8 | 73 | 32 000 | 14 | CBL | NS |
Patient . | Age, y . | Lymphocytosis, mm3 . | Duration from diagnosis, y . | Previous therapy . | CER accumulation, % . |
|---|---|---|---|---|---|
| 1 | 80 | 38 600 | 0 | No | +41 |
| 2 | 58 | 32 600 | 0.3 | No | +75 |
| 3 | 60 | 82 000 | 0 | No | +23 |
| 4 | 74 | 59 800 | 0 | No | +36 |
| 5 | 66 | 30 600 | 4 | CBL, CVP | NS |
| 6 | 66 | 70 100 | 11 | CBL, CVP | +80 |
| 7 | 75 | 19 100 | 11 | CBL | +13 |
| 8 | 73 | 32 000 | 14 | CBL | NS |
Variation of intracellular CER concentration was assayed by using the DAG kinase assay. CBL indicates chlorambucil; CVP, cyclophosphamide, vincristine, prednisone; NS, not significant.